et the query remains on ways to predict these complications. It really is relevant to think about prophylactic measures for avoiding hypercoagulability. Progressive diffuse abdominal pain with no significant alterations on coagulation profile or other danger aspects really should raise the awareness for mesenteric thrombosis. Really, handful of circumstances of intestinal thrombosis exist within the literature taking into consideration our patient one of the first circumstances of subacute mesenteric venous thrombosis inside a non-severe COVID-19 patient. Additional case reports and descriptive data are needed within the literature to enhance the index of suspicion for these types of complications.research concluding that there is no distinction in collateral formation, recanalization and mortality, no matter if CBP/p300 Activator manufacturer anticoagulation had been prescribed or not. These findings emphasize the predominant role of inflammation, growing KDM4 Inhibitor Formulation uncertainty of risk/benefit ratio of anticoagulation. When portal and superior mesenteric veins are affected, anticoagulation seems a affordable attitude, considering the risk of hepatic decompensation and bowel ischemia. Much more research are needed to consolidate this evidence and to establish well-defined recommendations in other circumstances (e.g., isolated thrombosis of splenic vein, as within this case).V T E D I AG N O S I S PB1175|Detection of Proper Ventricular Dysfunction in Acute Pulmonary Embolism by CT Scan: A Systematic Critique and Metaanalysis N. Chornenki1; K. Poorzargar2; M. Shanjer2; L. Mbuagbaw2;PB1174|Does Anticoagulation Affect Outcome of Splenic Vein Thrombosis in Acute Pancreatitis L. Vieira; S. Lopes; R. Pombal; R. Neto; A. Magalh s; M. Figueiredo Immunohemotherapy Service, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal Background: Splanchnic venous thrombosis (SVT) is usually a wellestablished complication of acute pancreatitis (AP) and may well impact splenic, portal and superior mesenteric veins, either isolated or in combination. Its pathogenesis is closely linked to inflammation, leading to cellular infiltration, formation of pancreatic/peripancreatic collections that contribute to venous stasis and systemic activation of haemostasis. Aims: Description of a case of SVT AP-associated. Strategies: Collection of clinical information in SCl ico application. Final results: A 47-year-old female patient, with antecedents of prior AP secondary to hypertriglyceridemia, was admitted to emergency division with pain in upper quadrants of abdomen, radiating towards the back, with nausea and vomiting, over the previous handful of hours. By way of clinical, analytical and imaging evaluation, the diagnosis of AP secondary to hypertriglyceridemia was established. The patient was hospitalized and, four days later, as a consequence of clinical worsening, a computed tomography (CT) was performed, revealing splenic vein thrombosis and pancreatic necrosis. Enoxaparin in therapeutic dose was initiated. The patient remained hospitalized for 18 days and enoxaparin was replaced by rivaroxaban 20mg as soon as each day at discharge. Three months later, CT showed persistence of thrombosis, with perigastric/perisplenic collateral circulation. Taking into consideration this in depth collateral circulation, full recanalization was no longer expected. Anticoagulation was maintained for any total period of 6 months. Conclusions: Management of thrombosis in AP remains difficult. There is no consensus on anticoagulation within this setting, with someM. Crowther2; A. Delluc3; D. SiegalQueens University, Kingston, Canada; 2McMaster University,Hamilton, Cana